{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:55Z","timestamp":1792787275441,"version":"4.5.0"},"reference-count":52,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"School of Nursing, Suzhou Medical College of Soochow University","award":["ZYQH-2026-39"],"award-info":[{"award-number":["ZYQH-2026-39"]}]},{"name":"The Pre-research Fund Project of the Second Affiliated Hospital of Soochow University","award":["SDFEYHL2448"],"award-info":[{"award-number":["SDFEYHL2448"]}],"id":[{"id":"https:\/\/ror.org\/02xjrkt08","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Suzhou Medical Center","award":["SZLCYXZX202103"],"award-info":[{"award-number":["SZLCYXZX202103"]}]},{"name":"Nursing Research Project of Suzhou Nursing Association","award":["SZHL-B-202609"],"award-info":[{"award-number":["SZHL-B-202609"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,10]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to systematically retrieve and synthesise the best available evidence on the management of immune-related cutaneous adverse events (ircAEs) associated with immune checkpoint inhibitors (ICIs) in patients with cancer, thereby providing evidence-based guidance for the development of assessment and management protocols in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This study was conducted as an evidence summary following the evidence summary reporting standard of the Fudan University Center for Evidence-Based Nursing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Evidence was searched across clinical decision support resources, guideline repositories, professional society websites and bibliographic databases, including UpToDate, BMJ Best Practice, Joanna Briggs Institute (JBI), National Comprehensive Cancer Network, European Society for Medical Oncology, American Society of Clinical Oncology, Cochrane Library, Embase, PubMed, Web of Science and major Chinese databases. Searches were conducted up to 23 December 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Evidence sources concerning the assessment, prevention or management of ircAEs in adults aged \u226518 years receiving ICIs were eligible. Clinical practice guidelines, expert consensus statements, evidence summaries, systematic reviews, clinical decision support resources and relevant original studies, including observational and quasi-experimental studies, published in Chinese or English were considered for inclusion. Duplicate publications, superseded guidelines and evidence sources that did not meet the predefined methodological quality criteria were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Two reviewers independently screened eligible evidence sources, extracted data and conducted methodological quality appraisal using design-appropriate tools, including the Appraisal of Guidelines for Research and Evaluation II and JBI critical appraisal instruments. Evidence was classified according to the JBI levels of evidence and evaluated for strength of recommendation using the feasibility, appropriateness, meaningfulness and effectiveness framework. Evidence with similar content was compared, integrated and synthesised into practice-oriented evidence statements, with disagreements resolved through discussion or consultation with a third reviewer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 21 evidence sources were included, comprising nine clinical practice guidelines, five expert consensus statements, two systematic reviews, two evidence summaries, one observational study, one quasi-experimental study and one clinical decision support resource. 29 evidence statements were synthesised across seven domains: risk factor identification, assessment and diagnosis, severity-based treatment, supportive nursing care, follow-up management, patient education and healthcare professional training. The synthesised evidence emphasised baseline skin assessment and early recognition of ircAEs, standardised severity grading, severity-based treatment escalation, phenotype-oriented supportive skin care, structured follow-up, patient and caregiver education, and timely multidisciplinary referral for severe or complex cutaneous toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The evidence provides a structured basis for standardising ircAEs screening, nursing assessment, symptom management, referral and follow-up in patients receiving ICIs. It may also support oncology nurses in strengthening patient and caregiver education, promoting timely symptom reporting and self-management and facilitating multidisciplinary referral for severe or atypical cutaneous toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-122459","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:12:07Z","timestamp":1790179927000},"page":"e122459","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Management of immune-related cutaneous adverse events associated with immune checkpoint inhibitors in patients with cancer: an evidence summary"],"prefix":"10.1136","volume":"16","author":[{"given":"Qi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nursing, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenting","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Nursing, Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nursing, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Nursing, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Tan","sequence":"additional","affiliation":[{"name":"School of Nursing, Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4331-126X","authenticated-orcid":false,"given":"Zhenzhu","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Nursing, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092309102448000_16.9.e122459.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026092309102448000_16.9.e122459.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00278-X"},{"key":"2026092309102448000_16.9.e122459.3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol"},{"key":"2026092309102448000_16.9.e122459.4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026092309102448000_16.9.e122459.5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","article-title":"Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis","volume":"159","author":"Du","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2026092309102448000_16.9.e122459.6","doi-asserted-by":"crossref","first-page":"104330","DOI":"10.1016\/j.lpm.2025.104330","article-title":"Update on dermatological toxicities of immune checkpoint inhibitors","volume":"55","author":"Fattore","year":"2026","journal-title":"Presse Med"},{"key":"2026092309102448000_16.9.e122459.7","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1111\/jocn.17154","article-title":"Patients\u2019 experiences of cancer immunotherapy with immune checkpoint inhibitors: A systematic review and thematic synthesis","volume":"33","author":"Watts","year":"2024","journal-title":"J Clin Nurs"},{"key":"2026092309102448000_16.9.e122459.8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u201cDermatology for cancer patients\u201d position statement","volume":"36","author":"Apalla","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092309102448000_16.9.e122459.9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/jdv.70149","article-title":"Prevention and management of cutaneous immune-related adverse events: EADV Task Force statement","volume":"40","author":"Fattore","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092309102448000_16.9.e122459.10","unstructured":"Zheng J , Liu T , Zheng X , et al . Summary of best evidence for the prevention and management of immune checkpoint inhibitor-related skin toxicity in lung cancer patients. 2023."},{"key":"2026092309102448000_16.9.e122459.11","first-page":"46","article-title":"Evidence-based summary of the management for immune checkpoint inhibitor-related cutaneous toxicity","volume":"39","author":"Yang","year":"2024","journal-title":"J Nurs Sci"},{"key":"2026092309102448000_16.9.e122459.12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026092309102448000_16.9.e122459.13","first-page":"1991","article-title":"The composition of different types of evidence based problems","volume":"32","author":"Zhu","year":"2017","journal-title":"J Nurses Train"},{"key":"2026092309102448000_16.9.e122459.14","doi-asserted-by":"publisher","DOI":"10.1136\/ebn.12.4.99-b"},{"key":"2026092309102448000_16.9.e122459.15","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090449"},{"key":"2026092309102448000_16.9.e122459.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"2026092309102448000_16.9.e122459.17","first-page":"996","article-title":"Promotion evidence to clinical transformation: evidence resource retrieval for the purpose of clinical transformation","volume":"35","author":"Zhu","year":"2020","journal-title":"J Nurses Train"},{"key":"2026092309102448000_16.9.e122459.18","unstructured":"Aromataris E , Munn Z . JBI manual for evidence synthesis. 2020."},{"key":"2026092309102448000_16.9.e122459.19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/jocn.16934","article-title":"Best evidence summary for prevention and management of enteral feeding intolerance in critically ill patients","volume":"33","author":"Peng","year":"2024","journal-title":"J Clin Nurs"},{"key":"2026092309102448000_16.9.e122459.20","first-page":"964","article-title":"JBI evidence pre-classification and evidence rank system","volume":"30","author":"Wang","year":"2014","journal-title":"J Nurses Train"},{"key":"2026092309102448000_16.9.e122459.21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026092309102448000_16.9.e122459.22","unstructured":"Chinese Society of Clinical Oncology (CSCO) Guideline Working Committee . CSCO guidelines for the management of immune checkpoint inhibitor-related toxicities: 2025. People\u2019s Medical Publishing House, 2025."},{"key":"2026092309102448000_16.9.e122459.23","first-page":"6119","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors","volume":"28","author":"Choi","year":"2020","journal-title":"Support Care Cancer"},{"key":"2026092309102448000_16.9.e122459.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026092309102448000_16.9.e122459.25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12094-019-02273-x","article-title":"SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)","volume":"22","author":"Majem","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"2026092309102448000_16.9.e122459.26","unstructured":"National Comprehensive Cancer Network . Management of immune checkpoint inhibitor-related toxicities (version 1.2025). 2025."},{"key":"2026092309102448000_16.9.e122459.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2026092309102448000_16.9.e122459.28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/1759-7714.13275","article-title":"Management of immune checkpoint inhibitor-related dermatologic adverse events","volume":"11","author":"Si","year":"2020","journal-title":"Thorac Cancer"},{"key":"2026092309102448000_16.9.e122459.29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamaoncol.2021.4318","article-title":"Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review","volume":"8","author":"Nadelmann","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026092309102448000_16.9.e122459.30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaad.2020.04.058","article-title":"Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review","volume":"83","author":"Simonsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026092309102448000_16.9.e122459.31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007675","article-title":"Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026092309102448000_16.9.e122459.32","first-page":"1790","article-title":"[Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition)]","volume":"104","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2026092309102448000_16.9.e122459.33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"2026092309102448000_16.9.e122459.34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s44272-025-00043-1","article-title":"Multi-disciplinary expert consensus on cutaneous adverse events caused by immune checkpoint inhibitors (2025)","volume":"4","author":"Sun","year":"2025","journal-title":"Clin Cancer Bull"},{"key":"2026092309102448000_16.9.e122459.35","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/ced\/llaf173","article-title":"Grade 3 and grade 4 cutaneous toxicities in patients with multiple solid tumour types receiving checkpoint inhibitor therapy: an observational study. The experience of a single large specialist institution","volume":"50","author":"Sharif","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026092309102448000_16.9.e122459.36","first-page":"2535","article-title":"Construction and application of nursing programme for immune checkpoint inhibitors-related skin toxicity in lung cancer patients","volume":"39","author":"Zheng","year":"2025","journal-title":"Chin Nurs Res"},{"key":"2026092309102448000_16.9.e122459.37","unstructured":"Patel AB . Cutaneous immune-related adverse events associated with immune checkpoint inhibitors. 2025."},{"key":"2026092309102448000_16.9.e122459.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02141"},{"key":"2026092309102448000_16.9.e122459.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjon.2022.100076","article-title":"Exploring the educational needs for severe immune-related adverse events of PD-1\/PD-L1 inhibitors in advanced lung cancer: A single-center observational study","volume":"9","author":"Aso","year":"2022","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2026092309102448000_16.9.e122459.40","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1002\/onco.13812","article-title":"The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors","volume":"26","author":"George","year":"2021","journal-title":"Oncologist"},{"key":"2026092309102448000_16.9.e122459.41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"2026092309102448000_16.9.e122459.42","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/jdv.19112","article-title":"Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study","volume":"37","author":"L\u2019Orphelin","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092309102448000_16.9.e122459.43","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad257"},{"key":"2026092309102448000_16.9.e122459.44","doi-asserted-by":"crossref","first-page":"7119579","DOI":"10.1155\/dth\/7119579","article-title":"Experiences of cutaneous immune\u2010related adverse events: a qualitative study in patients with cancer receiving immune checkpoint inhibitors","volume":"2025","author":"Yang","year":"2025","journal-title":"Dermatol Ther"},{"key":"2026092309102448000_16.9.e122459.45","article-title":"From supportive care to strategic intervention: toward a multidisciplinary approach to cutaneous adverse events in cancer treatment","volume":"33","author":"Fattore","year":"2025","journal-title":"Support Care Cancer"},{"key":"2026092309102448000_16.9.e122459.46","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjmed.2024.08.025","article-title":"Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors","volume":"137","author":"Hoimes","year":"2024","journal-title":"Am J Med"},{"key":"2026092309102448000_16.9.e122459.47","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S247554"},{"key":"2026092309102448000_16.9.e122459.48","doi-asserted-by":"crossref","DOI":"10.1002\/pon.70100","article-title":"Patient and Caregiver Education to Support Self-Efficacy and Self-Management During Immunotherapy-An Integrative Review","volume":"34","author":"Rothausen","year":"2025","journal-title":"Psychooncology"},{"key":"2026092309102448000_16.9.e122459.49","article-title":"Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"31","author":"da Silva Lopes","year":"2023","journal-title":"Support Care Cancer"},{"key":"2026092309102448000_16.9.e122459.50","first-page":"684","article-title":"Learning about and living with toxicity: a qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers","volume":"32","author":"Falade","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026092309102448000_16.9.e122459.51","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/jdv.16849","article-title":"The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force","volume":"34","author":"Garbe","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092309102448000_16.9.e122459.52","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-122459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:12:16Z","timestamp":1790179936000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-122459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-122459"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-122459","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}